Login to Your Account

Clinic Roundup

Thursday, October 18, 2012

• Neuralstem Inc., of Rockville, Md., said it started dosing in the second cohort of patients in its Phase Ib trial testing NSI-189 in major depressive disorder. The study is enrolling 24 patients, and the Phase Ib portion is expected to take about six months to complete. NSI-189 is a small molecule designed to stimulate new neuron growth in the hippocampus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription